



LucidQuest Intelligence
Accelerate your success

**63rd ERA
CONGRESS**
GLASGOW & VIRTUAL
JUNE 3-6, 2026

ERA 2026 Preview – Table of Contents

• <u>New Trends in Nephrology Strategy At ERA'26</u>	<u>3-5</u>
• <u>Key Sessions To Watch</u>	<u>6</u>
• <u>Industry-sponsored Sessions & Focus Areas At ERA 2026</u>	<u>7-13</u>
• <u>Competitive Landscape At a Glance at ERA 2026</u>	<u>8-9</u>
• <u>Key Industry-sponsored Sessions At ERA 2026</u>	<u>10-13</u>
• <u>New Entrants</u>	<u>14</u>
• <u>AI/ML Trends & Strategic Watchpoints At ERA 2026</u>	<u>15-18</u>
• <u>AI / Digital Health Angle At ERA 2026</u>	<u>16-18</u>
• <u>What We're Watching For Post-congress</u>	<u>19</u>
• <u>Get In Touch With LucidQuest</u>	<u>20</u>



ERA 2026 – New Trends in Nephrology Strategy (1/3)



- **IgAN will become the clearest mechanism-crowding battleground**

- ERA 2026 will feature IgAN readouts across atrasentan / ALIGN, iptacopan / APPLAUSE-IgAN, ravulizumab / I CAN, Nefecon / NefIgArd, atacicept / ORIGIN, and MY008211A Factor B inhibition. The strategic question will be whether differentiation shifts from proteinuria reduction toward durable eGFR separation, safety, and mechanism-based sequencing



- **Complement developers will test how far renal expansion can stretch**

- Sessions on pegcetacoplan in C3G and primary IC-MPGN, iptacopan in IgAN/C3G, crovalimab in aHUS, ravulizumab in IgAN/aHUS, and MY008211A in IgAN will show complement moving across rare and broader renal indications. The competitive tension will center on whether companies can define distinct patient-selection logic before complement positioning becomes crowded



ERA 2026 – New Trends in Nephrology Strategy (2/3)



• **Cardio-kidney-metabolic CKD will shift toward treatment sequencing**

- ERA 2026 will place finerenone / INFINITY, semaglutide / FLOW, empagliflozin/SGLT2i evidence, zilebesiran, nurandociguat, and rivaroxaban into overlapping high-risk CKD discussions. The unresolved question will be which mechanisms own earlier intervention in CKD patients with diabetes, hypertension, obesity, albuminuria, and cardiovascular risk



• **Biologics will challenge conventional immunosuppression in immune and rare kidney disease**

- Late-breaking and high-impact sessions on obinutuzumab / MAJESTY, rituximab / TURING, and imlifidase / GOOD-IDES-02 will increase pressure on tacrolimus, steroids, plasma exchange, and conventional immunosuppressive pathways. Broader rare-disease content across Fabry disease, nephropathic cystinosis, Alport syndrome, and anti-GBM disease will keep diagnosis, referral, and specialist-center access as commercial constraints



ERA 2026 – New Trends in Nephrology Strategy (3/3)



• **Dialysis differentiation will move from modality claims to outcomes evidence**

- ERA 2026 will feature trial evidence on **Theranova HDx**, including comparisons with **online HDF** and **DOPPS external real-world comparators**, alongside sessions on **HIF-PHI/anemia management**, **home dialysis support**, and **sustainability**. The commercial question is whether **HDx**, **home-care models**, **anemia strategies**, and **lower-resource dialysis approaches** can influence **procurement**, **reimbursement**, and **care-pathway decisions**



• **AI and digital nephrology will remain secondary, but workflow-relevant**

- ERA 2026 AI content will focus on **AI-based CKD risk assessment**, **Fresenius Medical Care's conversational AI support for home hemodialysis**, **AI-based dietary self-assessment in maintenance hemodialysis**, and **hybrid laboratory/home creatinine measurement**. The competitive tension will be whether these tools become embedded in **CKD detection**, **home dialysis confidence**, **nutritional management**, and **trial execution**, or remain isolated service-level experiments





Key Sessions To Watch

Date	Session Title (short)	Type	Author / Institution	Why Watch
04 June 2026	Atrasentan ALIGN 2.5-year eGFR	Late-breaking clinical trial (Symposium)	Hiddo J.L. Heerspink / UMC Groningen	Tests whether endothelin blockade can claim durable IgAN kidney-function preservation
04 June 2026	Iptacopan APPLAUSE-IgAN final data	Late-breaking clinical trial (Symposium)	Jonathan Barratt / University of Leicester	Important for Novartis' complement strategy in IgAN beyond proteinuria
04 June 2026	Semaglutide FLOW HRQoL in T2D CKD	Late-breaking clinical trial (Symposium)	Johannes Mann / FAU Erlangen	Adds patient-reported outcome context to GLP-1 positioning in CKD
05 June 2026	Finerenone pooled CKD analysis / INFINITY	Late-breaking clinical trial (Symposium)	Brendon Neuen / George Institute	Tests how broadly finerenone evidence can be extended across CKD populations
05 June 2026	Obinutuzumab vs tacrolimus / MAJESTY Trial	Late-breaking clinical trial (Symposium)	Fernando Custodio Fervenza / Mayo Clinic	Directly challenges tacrolimus-based management in primary membranous nephropathy.
05 June 2026	Crovalimab COMMUTE-a trial in aHUS	Late-breaking clinical trial (Symposium)	Bradley Dixon / University of Colorado	Important for next-generation C5 positioning against established eculizumab/ravulizumab use
06 June 2026	Ravulizumab I CAN in IgAN	High-impact clinical trial (Symposium)	Jonathan Barratt / University of Leicester	Tests whether C5 inhibition can become relevant in IgAN, not only aHUS
06 June 2026	Theranova HDx vs HDF outcomes	High-impact clinical trial (Symposium)	Roberto Pecoits-Filho / Arbor Research	Relevant for dialysis modality differentiation and real-world comparator strategy
06 June 2026	MY008211A oral Factor B inhibitor in IgAN	High-impact clinical trial (Symposium)	Ming Cheng / Shanghai Changzheng Hospital	Early signal for oral complement inhibition competing with iptacopan and ravulizumab narratives



Industry-Sponsored Sessions & Focus Areas – ERA 2026





ERA 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
IgAN targeted therapies	Multiple	Novartis / atrasentan, iptacopan; Calliditas / Nefecon; Alexion-AZ / ravulizumab; Vera / atacicept; MY008211A Factor B inhibitor	IgAN is the clearest mechanism-crowding battleground, with endothelin, complement, steroid, and BAFF/APRIL strategies competing for sequencing
Complement-driven renal disease	Multiple	Sobi-Apellis / pegcetacoplan; Novartis / iptacopan; Roche / crovalimab; Alexion-AZ / ravulizumab, eculizumab; MY008211A	Complement developers must prove where pathway inhibition has the strongest renal fit across IgAN, C3G, IC-MPGN, and aHUS
Cardio-kidney-metabolic CKD	Multiple	Bayer / finerenone, rivaroxaban, nurodiciguat; Novo Nordisk / semaglutide; SGLT2i class evidence; Alnylam / zilebesiran	CKD positioning is shifting toward earlier multimodal risk management across diabetes, hypertension, obesity, albuminuria, and CV risk
Immune GN / lupus nephritis	Multiple	Roche / obinutuzumab, rituximab; Hansa / imlifidase; tacrolimus, belimumab, voclosporin class context	Biologic strategies are challenging conventional immunosuppression in membranous nephropathy, lupus nephritis, and anti-GBM disease





ERA 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
Dialysis / anemia / home-care	Multiple	Theranova HDx; HIF-PHIs including desidustat; dialysis membrane, PD, and home-dialysis technologies	Dialysis differentiation is being framed around outcomes evidence, anemia management, home-care support, and system efficiency
Rare / genetic kidney disease	Multiple	Chiesi / Fabry, cystinosis; complement assets in C3G/aHUS; imlifidase in anti-GBM; Alport-related evidence	Rare nephrology is gaining visibility, but uptake depends on diagnosis, genetic testing, referral pathways, and specialist-center access
AI / digital nephrology	Multiple	Fresenius Medical Care / conversational AI; AI-based CKD risk algorithms; AI dietary self-assessment; hybrid creatinine measurement	Digital signals are most relevant where they support CKD detection, home dialysis, nutritional management, or trial execution



Key Industry-Sponsored Sessions at ERA 2026 (1/4)



- **Otsuka Pharmaceutical:**

- Focus Areas: [IgA Nephropathy](#), [Patient Burden & Disease-Specific Management](#)
- Sessions will address [IgAN patient burden](#), evolving guideline-based care, and [disease-specific approaches to limit nephron loss](#)



- **Boehringer Ingelheim:**

- Focus Areas: [CKD](#), [Cardio-Renal Protection & Podocytopathies](#)
- Sessions will focus on [early CKD intervention](#), [cardio-renal risk management](#), [GDMT](#), and emerging approaches in [podocytopathies](#) and [FSGS](#)



- **GSK/KDIGO:**

- Focus Areas: [Lupus Nephritis & CKD Vaccination Implementation](#)
- Sessions will address [sustained kidney preservation in lupus nephritis](#) and [practical vaccination workflows for adults with CKD](#)



Key Industry-Sponsored Sessions at ERA 2026 (2/4)

- **Roche Diagnostics:**

- Focus Areas: AI-Based CKD Risk Assessment
- Sessions will position AI-based algorithms as tools for personalized CKD risk assessment and earlier disease management

- **Chiesi:**

- Focus Areas: Nephropathic Cystinosis & Fabry Disease
- Sessions will focus on transition/transplantation care in cystinosis and molecular-to-clinical advances in Fabry disease

- **CSL:**

- Focus Areas: CKD-Associated Pruritus & Real-World Management
- Sessions will address patient perspectives, real-world case pathways, guideline implementation, and practical decision-making in CKD-associated pruritus



Key Industry-Sponsored Sessions at ERA 2026 (3/4)



- **Novartis:**

- Focus Areas: [IgA Nephropathy, C3G & Nephrology-Pathology Collaboration](#)
- Sessions will address [IgAN disease drivers, early diagnosis, updated KDIGO goals, evolving C3G care, and pathology-nephrology collaboration](#)



- **Samsung Bioepis:**

- Focus Areas: [aHUS Treatment Optimization & Eculizumab Withdrawal](#)
- Sessions will focus on evidence for [safe eculizumab discontinuation and treatment optimization](#) in adult and pediatric aHUS



- **Roche:**

- Focus Areas: [Lupus Nephritis Combination Therapy](#)
- Sessions will explore [early, individualized combination therapy](#) in lupus nephritis, including [timing, patient selection, and treatment personalization](#)



Key Industry-Sponsored Sessions at ERA 2026 (4/4)



- **AstraZeneca:**

- Focus Areas: UACR, Proteinuria & CKD Risk Stratification
- Sessions will focus on UACR use, proteinuria-driven progression, high-risk CKD identification, and integration into clinical practice



- **Bayer:**

- Focus Areas: CKD Risk Stratification, Cardio-Kidney Risk & Inflammation/Fibrosis
- Sessions will address cardio-kidney risk, precision stratification, and novel pathways targeting inflammation and fibrosis in non-diabetic CKD



New Entrants

Asset / Company	2026 Presence
Allele-specific therapies	Symposium: Open your mind to new therapeutic opportunities in inherited kidney diseases; Towards allele specific therapies: designing variant specific ASOs to cure inherited kidney diseases?
CLYM116	Oral: CLYM116, a Novel 'Sweeper' Anti-APRIL mAb: Extrapolation of PK and Ig Suppression from NHPs to Healthy Volunteers and Initial Phase 1 Data
Ricefidase	Oral: Early Repeated Administration of a Novel IgG-Degrading Enzyme Ricefidase for Anti-GBM Disease: A Phase 2, Open-Label, Single-Arm Multicenter Study
Tarperprumig	Properdin Inhibition as a Novel Therapeutic Strategy in ANCA-Associated Vasculitis: A Phase 2, Randomized, Double-Blind Clinical Trial of Tarperprumig
Novel Gene Therapy	Oral: Development of Novel Gene Therapy Approaches for the Treatment of Kidney Fibrosis in Diabetic Kidney Disease



AI/ML Trends & Strategic Watchpoints at ERA 2026





AI / Digital Health Angle at ERA 2026 (1/3)

- **AI/digital health at ERA 2026 represents a practical nephrology workflow signal, not a standalone technology theme. The concentration of sessions focused on AI-based CKD risk assessment, dialysis decision support, home hemodialysis confidence, intradialytic hypotension prevention, renal pathology annotation, nutrition management, diabetic nephropathy screening, and hybrid creatinine measurement suggests digital tools are being tested where they could influence earlier detection, dialysis safety, home-care support, and trial execution**
- **AI/ML activity at ERA 2026 is strategically relevant because it is tied to clinical workflow pressure points in nephrology rather than broad analytics. The most important signal is whether these tools can move from model development into use cases that affect CKD screening, dialysis risk management, home therapy adoption, nutritional management, and endpoint measurement in trials**
- **Key sessions include:**
 - Improving early CKD management through AI-based algorithms for personalized risk assessment
 - Improving Confidence in Home Hemodialysis Through Conversational AI-Driven Knowledge Access
 - A Prospective Study of an Explainable Real-Time AI System for Clinical Decision Support in Preventing Intradialytic Hypotension



AI / Digital Health Angle at ERA 2026 (2/3)

- Fast AI-Based Renal Tubule Annotation Using CD10–PAS Staining: An Experimental Clinical Study
- Effect of an AI-Based Dietary Self-Assessment System on Nutritional Management in Maintenance Hemodialysis Patients
- Identifying Multidimensional Risk Profiles in Dialysis Patients Using Unsupervised Machine Learning Clustering
- Hybrid laboratory and home-based creatinine measurement for eGFR endpoints in CKD and transplant trials
- Development and validation of the Kidney Klinrisk Algorithm: a machine learning model for predicting progressive kidney function decline
- Artificial intelligence–based screening model for early detection of diabetic nephropathy in patients with diabetes
- Generative AI-based image analysis of PD exit site: ready for prime time?
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - CKD detection and progression prediction through AI-based risk algorithms and diabetic nephropathy screening
 - Dialysis safety and personalization through intradialytic hypotension prediction, risk profiling, and clinical decision support



AI / Digital Health Angle at ERA 2026 (3/3)

- Home dialysis adoption through conversational AI, telemedicine-supported care, and digital patient support
- Nutrition and patient self-management through AI dietary assessment and renal meal-planning tools
- Trial execution and endpoint capture through hybrid laboratory/home creatinine measurement and eGFR endpoint support
- Pathology and peritoneal dialysis assessment through AI-based renal tubule annotation and PD exit-site image analysis



What We're Watching for Post-ERA 2026

- Whether **IgAN readouts** across atrasentan, iptacopan, ravulizumab, Nefecon, atacicept, and MY008211A show enough **eGFR durability** and **safety separation** to clarify **future sequencing**
- Whether **complement programs** including pegcetacoplan, iptacopan, crovalimab, ravulizumab, eculizumab, and MY008211A define clear **patient-selection logic** across **IgAN, C3G, IC-MPGN, and aHUS**
- Whether finerenone, semaglutide, SGLT2i evidence, zilebesiran, nurandociguat, and rivaroxaban shift **CKD discussion toward clearer cardio-kidney-metabolic treatment sequencing**
- Whether obinutuzumab, rituximab, and imlifidase generate enough evidence to challenge **tacrolimus, steroids, plasma exchange, and conventional immunosuppression**
- Whether **Theranova HDx evidence**, including comparisons with **OL-HDF** and **DOPPS real-world comparators**, strengthens **dialysis modality differentiation** beyond operational claims
- Whether **AI-based CKD risk assessment**, Fresenius Medical Care's conversational AI home hemodialysis support, AI dietary self-assessment, and **hybrid creatinine measurement** show **practical workflow value** in **CKD detection, home dialysis, nutritional management, or trial execution**



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM